Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Leukemia and Lymphoma Society (2319-19)
- License Information
-
More Information
Article History
Accepted: 14 January 2021
First Online: 28 January 2021
Compliance with Ethical Standards
:
: In the past 12 months, A.V.D. has received consulting fees from AstraZeneca, Abbvie, BeiGene, Genentech, TG Therapeutics, Janssen, Rigel Pharmaceutical, Nurix, Bayer Oncology, Karyopharm and Pharmacyclics and has ongoing research funding from AstraZeneca, Takeda Oncology, Gilead Sciences, Bayer Oncology, Genentech, Verastem Oncology, MEI and Bristol Myers Squibb.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
